Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Leerink Swann boosted their Q2 2017 earnings per share (EPS) estimates for shares of Amgen in a research note issued on Monday. Leerink Swann analyst G. Porges now anticipates that the medical research company will post earnings of $3.12 per share for the quarter, up from their previous estimate of $3.07. Leerink Swann currently has a “Market Perform” rating and a $161.00 target price on the stock. Leerink Swann also issued estimates for Amgen’s Q3 2017 earnings at $3.15 EPS, Q4 2017 earnings at $3.13 EPS and FY2017 earnings at $12.55 EPS.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.15. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. Amgen’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.90 EPS.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/19/leerink-swann-comments-on-amgen-inc-s-q2-2017-earnings-amgn.html.

Several other brokerages also recently issued reports on AMGN. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $189.00 price target on shares of Amgen in a research note on Thursday, April 6th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Robert W. Baird reaffirmed a “neutral” rating and set a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $195.00 price target on shares of Amgen in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and three have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $185.17.

Amgen (NASDAQ:AMGN) opened at 177.48 on Wednesday. The company has a market cap of $130.52 billion, a price-to-earnings ratio of 16.86 and a beta of 1.36. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21. The firm’s 50-day moving average price is $168.06 and its 200-day moving average price is $165.18.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Stralem & Co. Inc. increased its position in shares of Amgen by 0.6% in the second quarter. Stralem & Co. Inc. now owns 102,615 shares of the medical research company’s stock worth $17,673,000 after buying an additional 600 shares during the period. First Quadrant L P CA increased its position in Amgen by 80.4% in the second quarter. First Quadrant L P CA now owns 328,523 shares of the medical research company’s stock valued at $56,582,000 after buying an additional 146,396 shares during the period. Aperio Group LLC increased its position in Amgen by 9.1% in the second quarter. Aperio Group LLC now owns 365,006 shares of the medical research company’s stock valued at $62,865,000 after buying an additional 30,467 shares during the period. Tarbox Family Office Inc. increased its position in Amgen by 514.0% in the second quarter. Tarbox Family Office Inc. now owns 1,314 shares of the medical research company’s stock valued at $226,000 after buying an additional 1,100 shares during the period. Finally, Beech Hill Advisors Inc. increased its position in Amgen by 26.4% in the second quarter. Beech Hill Advisors Inc. now owns 2,003 shares of the medical research company’s stock valued at $345,000 after buying an additional 418 shares during the period. Institutional investors and hedge funds own 78.80% of the company’s stock.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.